Organising the right technology team is a pre-requisite for the deployment of success. However, ensuring that you…
On July 15, 2016, Biocon Ltd. announced the launch of a high quality, yet affordable biosimilar version of Sanofi’s blockbuster Lantus drug for patients of diabetes in Japan. Lantus, or Insulin Glargine, is a biologic. In contrast to conventional drugs that are synthesized from chemicals, a biologic is manufactured in a living system such as a microorganism or plant or animal cells. Most biologics are large, complex molecules and are produced using recombinant DNA technology. Biologics are one of the most significant developments of modern science as they potentially offer the most effective means to treat a variety of medical conditions that presently have no other treatments available……….
The 25 Best Companies to Work for in Asia